Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.
Shift Health and University Health Network (UHN) were engaged by Halton Healthcare to assess the current state of research across a multisite hospital system and define the future direction of its clinical research program.
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.
The University of Saskatchewan needed a compelling proposal to secure investment from the Canada First Research Excellence Fund (CFREF) for a water security research program.
The Saskatchewan Centre for Patient-Oriented Research (SCPOR) needed a third-party evaluation to understand its impact to date and optimize its strategy.
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.
Creating a Global Policy Strategy to Support the Launch of an Innovative Influenza Antiviral for a Top-5 Pharma Company
The global headquarters of a top-5 pharmaceutical company needed to develop a global policy strategy to support the launch of a new treatment for influenza.